A detailed history of Graypoint LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Graypoint LLC holds 2,905 shares of VRTX stock, worth $1.34 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
2,905
Previous 2,327 24.84%
Holding current value
$1.34 Million
Previous $972,000 40.02%
% of portfolio
0.1%
Previous 0.07%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$392.81 - $485.53 $227,044 - $280,636
578 Added 24.84%
2,905 $1.36 Million
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $35,876 - $39,255
88 Added 3.93%
2,327 $972,000
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $64,827 - $77,618
189 Added 9.22%
2,239 $911,000
Q3 2023

Oct 26, 2023

BUY
$338.18 - $362.46 $114,643 - $122,873
339 Added 19.81%
2,050 $712,000
Q2 2023

Jul 21, 2023

BUY
$314.42 - $351.91 $182,049 - $203,755
579 Added 51.15%
1,711 $602,000
Q1 2023

May 02, 2023

BUY
$283.23 - $323.1 $88,367 - $100,807
312 Added 38.05%
1,132 $356,000
Q4 2022

Jan 31, 2023

BUY
$285.76 - $321.48 $5,143 - $5,786
18 Added 2.24%
820 $236,000
Q3 2022

Oct 31, 2022

BUY
$273.83 - $305.53 $219,611 - $245,035
802 New
802 $232,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Graypoint LLC Portfolio

Follow Graypoint LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graypoint LLC, based on Form 13F filings with the SEC.

News

Stay updated on Graypoint LLC with notifications on news.